Back to Blog
Vmt academy5/6/2023 ![]() ![]() The presence of SFL at baseline was associated with worse VA, and its ![]() Additionally, eyes that demonstrated SFL within the first 2 weeks after ocriplasmin treatment showed similar visual acuity at month 6 compared with eyes without SFL over the course of the study. This study showed that SFL is present among a significant proportion of eyes with symptomatic VMA or VMT and that the incidence of this finding increased transiently after ocriplasmin treatment and then resolved within a few months. The results are stratified based on whether ocriplasmin or placebo was administered, whether SFL was present, and whether VMT or VMA release occurred. Thirty-one of the 357 eyes (8.7%) in the ocriplasmin group and 20 of the 142 eyes (14.1%) in the placebo group underwent PPV. Of these eyes, 357 were randomized to ocriplasmin and 142 were randomized to placebo. All data were managed in compliance with the Health Insurance Portability and Accountability Act and Study Participantsįour hundred ninety-nine eyes of 499 patients with VMT or symptomatic VMA without MH were included in this study. Our study was approved by the Duke University Institutional Review Board. The study protocol has been published previously. The trial was approved by the respective institutional review boards of the participating clinical sites, and each participant provided informed written consent. ![]() The MIVI-TRUST program recruited 652 patients from 90 clinical sites across the United States and Europe. In the placebo group, those with baseline SFL showed low rates of spontaneous VMT release at month 6 compared with those without baseline SFL (3/21 eyes vs. Among ocriplasmin-treated eyes at month 6, those with SFL and VMT release had better VA than those with SFL and persistent adhesion ( P = 0.037) and similar VA to those with persistent adhesion without SFL ( P = 0.17). The increase in SFL width from baseline to week 2 was significantly greater with ocriplasmin than placebo ( P = 0.029). In placebo-treated eyes but not ocriplasmin-treated eyes, SFL was associated with worse VA at all visits. Six-month VA for eyes demonstrating SFL after ocriplasmin during the first 2 weeks was comparable with those without SFL at any point in the study ( P = 0.12). Among eyes without baseline SFL, new SFL was more frequent after ocriplasmin than placebo at week 1 (23.1% vs. ![]()
0 Comments
Read More
Leave a Reply. |